Lv4
684 积分 2021-07-08 加入
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
2天前
已完结
Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study
2天前
已完结
Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling
2天前
已完结
Consensus on standardized later-line systemic therapy for hepatocellular carcinoma
2天前
已完结
Transketolase-like 1 potentiates PD-1 blockade in hepatocellular carcinoma by glycolysis to prime dendritic cell lactylation
3天前
已完结
USP10 stabilizes FOXM1 through KAT5-mediated acetylation to suppress cell senescence and promote melanoma malignant progression
4天前
已完结
Nucleolin shields PTBP1 from autophagic degradation to sustain gemcitabine resistance in bladder cancer
4天前
已完结
TRIM27-Cas9-loaded EVs suppress HCC proliferation and enhance responsiveness to anti-PD-1 therapy by promoting ACSL4-mediated ferroptosis
5天前
已完结
USP14 competitively binds to FBXW7 to stabilize MTDH and promotes metastasis and drug resistance of head and neck squamous cell carcinoma
5天前
已完结
The ABHD10-ACSL4 axis promotes pancreatic ductal adenocarcinoma growth via suppressing ferroptosis
5天前
已完结
皖公网安备34019202002308
